Prostaglandin E2 Induces MIR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression.
Prostaglandin E2 (PGE2) promotes colorectal tumor formation and progression by unknown mechanisms. We sought to identify microRNAs (miRNAs) might mediate the effects of PGE2 on colorectal cancer (CRC) development. We incubated LS174T colorectal cancer cells with PGE2 or without (control) and used miRNA-seq technology to compare expression patterns of miRNAs. We knocked down levels of specific miRNAs or proteins in cells using small interfering RNAs or genome editing. Cells were analyzed by immunoblot, quantitative PCR, chromosome immunoprecipitation, cell invasion, and luciferase reporter assays; we measured gene expression, binding activity, cell migration and invasion, and transcriptional activity of transcription factors. NSG mice were given injections of LS174T cells and growth of primary tumors and numbers of liver and lung metastases were quantified and analyzed by histology. We used public databases to identify correlations in gene expression pattern with patient outcomes. We identified miRNA 675-5p (MIR675-5p) as the miRNA most highly upregulated by incubation of colorectal cancer cells with PGE2. PGE2 increased expression of MIR675-5p by activating expression of Myc, via activation of AKT, NF-κB, and β-catenin. PGE2 increased the invasive activities of cultured CRC cells. LS174T cells incubated with PGE2 formed more liver and lung metastases in mice than control LS174T cells. We identified a 3'UTR in the TP53 mRNA that bound MIR675-5p; binding resulted in loss of the p53 protein. Expression of MIR675-5p or its precursor RNA, H19, correlated with expression of cyclooxygenase-1 and cyclooxygenase-2 and shorter survival times of patients with CRC. We found incubation of CRC cells with PGE2 to increase their invasive activity and ability to form liver and lung metastases in mice. PGE2 downregulates expression of p53 by increasing expression of MIR675-5p, which binds to and prevents translation of TP53 mRNA. These findings provide insight into the mechanisms by which PGE2 promotes tumor development and progression. Strategies to target the PGE2 might be developed for treatment of CRC.